Trinity Biotech's CGM Sensor Receives Positive Clinical Trial Results, Poised for Commercialization

Trinity Biotech has announced positive clinical trial results for its next-generation continuous glucose monitoring (CGM) technology, CGM+. The redesigned sensor delivers accurate glucose readings for 15 days without finger-stick calibration and reduces disposable components, lowering the cost of care. The innovative approach is expected to enhance accessibility and adoption of CGM technology, addressing the high cost of existing devices. The global CGM market is projected to grow from $13 billion in 2025 to $28 billion by 2030, driven by rising diabetes prevalence and demand for real-time health data.